[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553119":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":22,"armGroups":23,"interventions":29,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":82,"collaborators":84,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":18,"enrollmentInfo":99,"targetDuration":18,"studyType":102,"phases":18,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":48,"whyStopped":18,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"SB Technology, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Relationship between pre-procedural MCG and the peri-procedural angiography-based measures","Utilize linear regression and logistic regression to determine whether a set of a priori MCG-based biomarkers can prospectively predict the objective clinical assessment of ACS, while statistically adjusting for covariates.","Data taken within 24 hours of each other",[14],{"measure":15,"description":16,"timeFrame":17},"Sponsor MCG device safety","Device-related adverse events","30 days",null,{"allocation":18,"interventionModel":18,"interventionModelDescription":18,"primaryPurpose":18,"observationalModel":20,"timePerspective":21,"maskingInfo":18},"COHORT","PROSPECTIVE","Adult patients who are undergoing a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute coronary syndrome (ACS).",[24],{"label":25,"type":18,"description":26,"interventionNames":27},"ACS","Adult patients who are undergoing a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute coronary syndrome (ACS). Patients are further classified as having low, medium, and high risk for ACS.",[28],"Device: Sponsor MCG device (CardiAQ)",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":18},"DEVICE","Sponsor MCG device (CardiAQ)","Unshielded magnetocardiography device for measuring cardiac magnetic fields",[25],[36],{"name":37,"affiliation":5,"role":38},"Kit Yee Au-Yeung, PhD","STUDY_DIRECTOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":18,"email":44},"Maggie LeDang","CONTACT","408-981-8754","clinical-trials@sandboxquantum.com",[46,68],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Mayo Clinic","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-92.4699,44.02163,{"lat":58,"lon":57},[61,65],{"name":62,"role":42,"phone":63,"phoneExt":18,"email":64},"Ghasaq Saleh, MD","5072552504","saleh.ghasaq@mayo.edu",{"name":66,"role":67,"phone":18,"phoneExt":18,"email":18},"Mohamad A Alkhouli, MD, MBA","PRINCIPAL_INVESTIGATOR",{"facility":69,"status":48,"city":70,"state":70,"zip":71,"country":52,"countryCode":53,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Mount Sinai Hospital","New York","10029",{"type":55,"coordinates":73},[74,75],-74.00597,40.71427,{"lat":75,"lon":74},[78],{"name":79,"role":42,"phone":80,"phoneExt":18,"email":81},"Sajiny John","631-750-6345","sajiny.john@mountsinai.org",{"type":83,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[85,87],{"name":47,"class":86},"OTHER",{"name":88,"class":86},"Icahn School of Medicine at Mount Sinai","100553119","a-prospective-research-investigation-of-ischemia-using-mcg-100553119",false,"NCT06481943","A Prospective Research Investigation of Ischemia Using MCG","A Prospective Research Investigation of Ischemia Using SandboxAQ Magnetocardiography Device","PRISM\u002FPRISM2","Inclusion Criteria:\n\n* Scheduled to undergo a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute myocardial infarction\n* Ability for participant to comply with study requirements\n* Patient consented before the planned, clinically indicated cath-lab procedure begins to allow sufficient time for study related activities\n* Written informed consent\n\nExclusion Criteria:\n\n* Present STEMI\n* Pregnant or breastfeeding\n* Having an active atrial fibrillation episode as seen on most current 12-lead ECG\n* Active thoracic metal implant\n* Poor access to follow-up","ALL","18 Years",{"count":100,"type":101},335,"ESTIMATED","OBSERVATIONAL","PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.",[105],"Acute Coronary Syndrome",[107,108],"Magnetocardiography","MCG","2026-09-01",{"date":111,"type":112},"2026-09-04","ACTUAL",{"date":114,"type":112},"2024-07-11",{"date":116,"type":101},"2027-02",{"name":5,"class":6},2]